Cargando…

COPD and glycopyrronium responsiveness assessment: An appraisal

BACKGROUND: Glycopyrronium bromide (a long-acting antimuscarinic agent: LAMA) appears pharmacokinetically suitable for testing bronchodilator responsiveness as salbutamol (short-acting β2-agonist: SABA). Exploring the feasibility, acceptability, degree of reversibility with glycopyrronium, and its c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhattacharyya, Parthasarathi, Saha, Dipanjan, Chatterjee, Moumita, Sengupta, Sayoni, Dey, Debkanya, Banerjee, Rajat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10298818/ https://www.ncbi.nlm.nih.gov/pubmed/37148020 http://dx.doi.org/10.4103/lungindia.lungindia_376_22

Ejemplares similares

The impact of lockdown on symptoms and health status of patients with chronic airway diseases: An appraisal of patient perceived impressions
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2023)

Correlating between chronic obstructive pulmonary disease assessment test and emPHasis score in Group III pulmonary hypertension patients
por: Sengupta, Sayoni, et al.
Publicado: (2019)

Long-term use of Vitamin-C in chronic obstructive pulmonary disease: Early pilot observation
por: Dey, Debkanya, et al.
Publicado: (2021)

High-resolution computerized tomography changes in diffuse parenchymal lung disease from chronic hypersensitivity pneumonitis related to bird antigen
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2018)

The impact on health status in short- and long-terms of a novel and non-orthodox real-world COPD rehabilitation effort in rural India: an appraisal
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2018)

Prevalence and health status of COPD in rural West Bengal
por: Ghosh, Rupak Kumar, et al.
Publicado: (2022)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022)

Correction to: Budesonide/Glycopyrronium/Formoterol: A Review in COPD
por: Heo, Young-A
Publicado: (2021)

Tuberculosis associated pulmonary hypertension: The revelation of a clinical observation
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2016)

Cost-Effectiveness of Dual Bronchodilator Indacaterol/Glycopyrronium for COPD Treatment in China
por: Gong, Shiyi, et al.
Publicado: (2021)

The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Guo, Min, et al.
Publicado: (2022)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD
por: Buhl, Roland, et al.
Publicado: (2012)

A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD
por: Rheault, Tara, et al.
Publicado: (2016)

Anti-p-benzoquinone antibody level as a prospective biomarker to identify smokers at risk for COPD
por: Banerjee, Santanu, et al.
Publicado: (2017)

Role of doxycycline to resolve different types of non-malignant lung and pleural pathology: The results of a pilot observation
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2015)

Long-term doxycycline and lung function in chronic obstructive pulmonary disease: A pilot observation
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2014)

Critical clinical appraisal of the role of computed tomography-guided minimally invasive aspiration cytology in evaluation of retroperitoneal masses
por: Das, Chhanda, et al.
Publicado: (2014)

Retracted: The Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol in the Treatment of COPD in the Elderly
por: Imaging, Contrast Media & Molecular
Publicado: (2023)

Profile of glycopyrronium for once-daily treatment of moderate-to-severe COPD [Corrigendum]
Publicado: (2014)

Role of once-daily glycopyrronium bromide (NVA237) in the management of COPD
por: D’Urzo, Anthony
Publicado: (2013)

The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients
por: Sanguinetti, Claudio M
Publicado: (2014)

Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial
por: Singh, Dave, et al.
Publicado: (2022)

A novel model-based approach for dose determination of glycopyrronium bromide in COPD
por: Arievich, Helen, et al.
Publicado: (2012)

The increasing trend and the seasonal variation in attendance of diffuse parenchymal lung disease patients presenting to a pulmonary clinic in Eastern India
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2021)

Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan
por: Horita, Nobuyuki, et al.
Publicado: (2015)

Management of severe COPD exacerbations: focus on beclomethasone dipropionate/formoterol/glycopyrronium bromide
por: Mantero, Marco, et al.
Publicado: (2018)

Patient-reported outcomes and considerations in the management of COPD: focus on indacaterol/glycopyrronium bromide
por: Ridolo, Erminia, et al.
Publicado: (2019)

Cost-effectiveness analysis of a fixed-dose combination of indacaterol and glycopyrronium as maintenance treatment for COPD
por: Chan, Ming-Cheng, et al.
Publicado: (2018)

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD
por: Anzueto, Antonio R, et al.
Publicado: (2017)

Safety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data
por: D’Urzo, Anthony D, et al.
Publicado: (2015)

Efficacy and safety of indacaterol/glycopyrronium in Japanese patients with COPD: a subgroup analysis from the SHINE study
por: Hashimoto, Shu, et al.
Publicado: (2016)

Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPD
por: Prakash, Anoop, et al.
Publicado: (2015)

Indacaterol and glycopyrronium versus indacaterol on body plethysmography measurements in COPD—a randomised controlled study
por: Salomon, Joerg, et al.
Publicado: (2017)

Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy
por: Dhungana, Santosh, et al.
Publicado: (2017)

Aquagenic palmoplantar keratoderma therapeutic response to topical glycopyrronium
por: Medhus, Emily J., et al.
Publicado: (2021)

Effects of combination therapy indacaterol/glycopyrronium versus tiotropium on moderate to severe COPD: evaluation of impulse oscillometry and exacerbation rate
por: Molino, Antonio, et al.
Publicado: (2017)

Impact of long-term doxycycline on lung function & exacerbations: A real-world open, prospective pilot observation on chronic obstructive pulmonary disease
por: Bhattacharyya, Parthasarathi, et al.
Publicado: (2021)

Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis
por: Vogelmeier, Claus, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_otf9bhdk4oq7jcu5c785hhg57i